Beyond Ensitrelvir: Computational Identification of Novel Inhibitors of SARS-CoV-2 Main Protease with Enhanced Binding Affinity
Updated: 41 minutes ago

SARS-CoV-2 main protease, also known as the 3C-like protease (3CLpro), is an important target for antiviral drug development because it plays an essential role in viral replication and has no close homolog in human cells. Several small-molecule inhibitors targeting 3CLpro have been developed, including ensitrelvir (EST), which has been approved for the treatment of COVID-19. In a randomized, placebo-controlled trial, EST was reported to reduce the relative risk of COVID-19 by 67% following high-risk household exposure. Intriguingly, further optimization of EST's binding properties to 3CLpro could potentially enhance its therapeutic efficacy. In my upcoming hypothesis, I employ a computational structure–binding relationship approach to design next-generation of EST with improved binding properties and therapeutic potential—stay tuned!
Read the Full Hypothesis with Preliminary Finding Now!




Comments